Assessment of the effectiveness of Budesonide MMX® for active, mild-to-moderate ulcerative colitis in the Polish sub-group of the CORE Practice prospective multi-centre observational study

Maciej Jesionowski; Grażyna Rydzewska; Silvio Danese; Kristine Paridaens

doi:10.5114/pg.2023.129413

Streszczenie

2/2023 vol. 18

Artykuł oryginalny

Assessment of the effectiveness of Budesonide MMX® for active, mild-to-moderate ulcerative colitis in the Polish sub-group of the CORE Practice prospective multi-centre observational study

Maciej Jesionowski ¹

,

Grażyna Rydzewska ^{2, 3}

,

Silvio Danese ⁴

,

Kristine Paridaens ⁵

Medical Affairs Ferring Pharmaceuticals Poland, Warsaw, Poland
Department of Internal Medicine and Gastroenterology with Inflammatory Bowel Disease Unit, Central Clinical Hospital of the Ministry of the Interior and Administration, Warsaw, Poland
Collegium Medicum, Jan Kochanowski University, Kielce, Poland
Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milano, Italy
Global Medical Affairs Ferring International Centre, St-Prex, Switzerland

Gastroenterology Rev 2023; 18 (2): 154–160

DOI: https://doi.org/10.5114/pg.2023.129413

Data publikacji online: 2023/07/27

Pełna treść artykułu

AMA

Jesionowski M, Rydzewska G, Danese S, Paridaens K. Assessment of the effectiveness of Budesonide MMX® for active, mild-to-moderate ulcerative colitis in the Polish sub-group of the CORE Practice prospective multi-centre observational study. Gastroenterology Review/Przegląd Gastroenterologiczny. 2023;18(2):154-160. doi:10.5114/pg.2023.129413.

APA

Jesionowski, M., Rydzewska, G., Danese, S., & Paridaens, K. (2023). Assessment of the effectiveness of Budesonide MMX® for active, mild-to-moderate ulcerative colitis in the Polish sub-group of the CORE Practice prospective multi-centre observational study. Gastroenterology Review/Przegląd Gastroenterologiczny, 18(2), 154-160. https://doi.org/10.5114/pg.2023.129413

Chicago

Jesionowski, Maciej, Grażyna Rydzewska, Silvio Danese, and Kristine Paridaens. 2023. "Assessment of the effectiveness of Budesonide MMX® for active, mild-to-moderate ulcerative colitis in the Polish sub-group of the CORE Practice prospective multi-centre observational study". Gastroenterology Review/Przegląd Gastroenterologiczny 18 (2): 154-160. doi:10.5114/pg.2023.129413.

Harvard

Jesionowski, M., Rydzewska, G., Danese, S., and Paridaens, K. (2023). Assessment of the effectiveness of Budesonide MMX® for active, mild-to-moderate ulcerative colitis in the Polish sub-group of the CORE Practice prospective multi-centre observational study. Gastroenterology Review/Przegląd Gastroenterologiczny, 18(2), pp.154-160. https://doi.org/10.5114/pg.2023.129413

MLA

Jesionowski, Maciej et al. "Assessment of the effectiveness of Budesonide MMX® for active, mild-to-moderate ulcerative colitis in the Polish sub-group of the CORE Practice prospective multi-centre observational study." Gastroenterology Review/Przegląd Gastroenterologiczny, vol. 18, no. 2, 2023, pp. 154-160. doi:10.5114/pg.2023.129413.

Vancouver

Jesionowski M, Rydzewska G, Danese S, Paridaens K. Assessment of the effectiveness of Budesonide MMX® for active, mild-to-moderate ulcerative colitis in the Polish sub-group of the CORE Practice prospective multi-centre observational study. Gastroenterology Review/Przegląd Gastroenterologiczny. 2023;18(2):154-160. doi:10.5114/pg.2023.129413.

Udostępnij

Dostępne w

Indeksowane w

Zintergrowane z

Zasady redakcyjne

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications